As companies pursue many different targets and modalities in search of the first and best therapy to treat the broad unmet medical need in non-alcoholic steatohepatitis (NASH), Promethera Biosciences SA NV is nearing clinical development in NASH fibrosis for its liver-derived stem cell candidate HepaStem, which has shown promising efficacy in animal models and appeared to be safe for pediatric patients.
Promethera presented a late-breaking poster during the American Association for the Study of Liver Diseases (AASLD) meeting in November that...